Credit Suisse Ag Iovance Biotherapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 2,008,046 shares of IOVA stock, worth $16.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,008,046

Previous 2,814,316 28.65%

Holding current value

$16.1 Million

Previous $22.9 Million 30.07%

% of portfolio

0.03%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$7.59 - $17.47 $6.12 Million - $14.1 Million	-806,270 Reduced 28.65%	2,008,046 $29.8 Million
Q4 2023 Feb 08, 2024	SELL	$3.3 - $8.89 $96,204 - $259,170	-29,153 Reduced 1.03%	2,814,316 $22.9 Million
Q3 2023 Nov 13, 2023	BUY	$4.44 - $8.79 $219,091 - $433,742	49,345 Added 1.77%	2,843,469 $12.9 Million
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $521,431 - $881,374	97,282 Added 3.61%	2,794,124 $19.7 Million
Q1 2023 May 10, 2023	BUY	$5.53 - $8.22 $172,878 - $256,973	31,262 Added 1.17%	2,696,842 $16.5 Million

Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $314,017 - $558,750	55,875 Added 2.14%	2,665,580 $17 Million
Q3 2022 Nov 10, 2022	SELL	$9.53 - $13.11 $272,529 - $374,906	-28,597 Reduced 1.08%	2,609,705 $25 Million
Q2 2022 Aug 12, 2022	BUY	$6.38 - $18.33 $898,106 - $2.58 Million	140,769 Added 5.64%	2,638,302 $29.1 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $751,676 - $1.16 Million	60,717 Added 2.49%	2,497,533 $41.6 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $350,909 - $585,838	21,203 Added 0.88%	2,436,816 $46.5 Million
Q3 2021 Nov 12, 2021	BUY	$20.35 - $26.63 $69,393 - $90,808	3,410 Added 0.14%	2,415,613 $59.6 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $289,269 - $585,801	17,714 Added 0.74%	2,412,203 $62.8 Million
Q1 2021 May 14, 2021	BUY	$28.67 - $52.59 $67.9 Million - $125 Million	2,368,369 Added 9067.26%	2,394,489 $75.8 Million
Q4 2020 Feb 12, 2021	SELL	$28.04 - $50.26 $830,320 - $1.49 Million	-29,612 Reduced 53.13%	26,120 $1.21 Million
Q3 2020 Nov 13, 2020	SELL	$27.75 - $36.3 $624,208 - $816,532	-22,494 Reduced 28.76%	55,732 $1.84 Million
Q2 2020 Aug 12, 2020	BUY	$27.21 - $41.0 $1.92 Million - $2.89 Million	70,598 Added 925.51%	78,226 $2.15 Million
Q1 2020 May 13, 2020	SELL	$19.54 - $38.85 $27.7 Million - $55.1 Million	-1,417,880 Reduced 99.46%	7,628 $228,000
Q4 2019 Feb 12, 2020	SELL	$17.95 - $29.41 $1.8 Million - $2.95 Million	-100,414 Reduced 6.58%	1,425,508 $39.5 Million
Q3 2019 Nov 12, 2019	SELL	$17.99 - $26.0 $798,468 - $1.15 Million	-44,384 Reduced 2.83%	1,525,922 $27.8 Million
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $3.13 Million - $7.85 Million	-319,988 Reduced 16.93%	1,570,306 $38.5 Million
Q1 2019 May 14, 2019	BUY	$8.41 - $11.26 $3,540 - $4,740	421 Added 0.02%	1,890,294 $18 Million
Q4 2018 Feb 13, 2019	BUY	$7.51 - $11.93 $2.47 Million - $3.93 Million	329,048 Added 21.08%	1,889,873 $16.7 Million
Q3 2018 Nov 13, 2018	BUY	$11.25 - $17.7 $5.96 Million - $9.37 Million	529,511 Added 51.34%	1,560,825 $17.6 Million
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $5.23 Million - $7.12 Million	-420,246 Reduced 28.95%	1,031,314 $13.2 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $2.88 Million - $6.94 Million	356,132 Added 32.51%	1,451,560 $24.5 Million
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $6.79 Million - $9.45 Million	1,021,734 Added 1386.45%	1,095,428 $8.76 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $209,786 - $403,072	47,143 Added 177.56%	73,694 $571,000
Q2 2017 Aug 14, 2017	BUY	N/A	26,551	26,551 $196,000

Others Institutions Holding IOVA

# of Institutions

303

Shares Held

221M

Call Options Held

3.05M

Put Options Held

1.6M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.27B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account